Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Daventure

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 20, 2020
V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc ReceptorSofia Rossini, Rémi Noé, Victoria Daventure, et al.
European Journal of Immunology|December 20, 2024
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion TechnologyVictoria Daventure, Melissa Bou-Jaoudeh, Emna Hannachi, et al.
ACS Omega|December 21, 2019
Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody PolyreactivityNina Božinović, Vladimir Ajdačić, Jelena Lazic, et al.
European Journal of Immunology|July 2, 2026
Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading EnzymeEmna Hannachi, Robin V Lacombe, Amélia Trecco, et al.
Frontiers in Immunology|June 2, 2020
Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune ToleranceAngelina Mimoun, Sandrine Delignat, Ivan Peyron, et al.
Haematologica|January 19, 2023
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A miceMelissa Bou-Jaoudeh, Sandrine Delignat, Victoria Daventure, et al.
Frontiers in Immunology|February 25, 2026
Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humansEmna Hannachi, Amélia Trecco, Victoria Daventure, et al.
Haematologica|March 13, 2025
Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptidesAlejandra Reyes-Ruiz, Sandrine Delignat, Aurélien Azam, et al.
Haematologica|December 12, 2024
Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extensionAlejandra Reyes-Ruiz, Sandrine Delignat, Aishwarya Sudam Bhale, et al.
Journal of Thrombosis and Haemostasis : JTH|July 20, 2023
Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumabMelissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|October 20, 2020
V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc ReceptorSofia Rossini, Rémi Noé, Victoria Daventure, et al.
European Journal of Immunology|December 20, 2024
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion TechnologyVictoria Daventure, Melissa Bou-Jaoudeh, Emna Hannachi, et al.
ACS Omega|December 21, 2019
Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody PolyreactivityNina Božinović, Vladimir Ajdačić, Jelena Lazic, et al.
European Journal of Immunology|July 2, 2026
Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading EnzymeEmna Hannachi, Robin V Lacombe, Amélia Trecco, et al.
Frontiers in Immunology|June 2, 2020
Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune ToleranceAngelina Mimoun, Sandrine Delignat, Ivan Peyron, et al.
Haematologica|January 19, 2023
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A miceMelissa Bou-Jaoudeh, Sandrine Delignat, Victoria Daventure, et al.
Frontiers in Immunology|February 25, 2026
Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humansEmna Hannachi, Amélia Trecco, Victoria Daventure, et al.
Haematologica|March 13, 2025
Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptidesAlejandra Reyes-Ruiz, Sandrine Delignat, Aurélien Azam, et al.
Haematologica|December 12, 2024
Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extensionAlejandra Reyes-Ruiz, Sandrine Delignat, Aishwarya Sudam Bhale, et al.
Journal of Thrombosis and Haemostasis : JTH|July 20, 2023
Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumabMelissa Bou-Jaoudeh, Angelina Mimoun, Sandrine Delignat, et al.
Pageof 2